PT20 is a novel iron-based phosphate binder that we are developing for the treatment of hyperphosphatemia. The integration of adipic acid to form PT20 increases the phosphate binding capacity by a factor of three, compared to the unmodified iron oxide. The manufacturing process also results in particles of a very small size, which maximises the surface available for phosphate binding.
PT20 is exclusively licensed from the Medical Research Council in the United Kingdom.
PT30 and PT40
PT30 is a novel IV iron formulation and PT40 is being developed to be the first generic version of iron sucrose.